The End of Rebate Sorcery: Why Point-of-Sale Rebates Change Everything for Employers

A policy brief on pharmacy rebates, employer leverage, and the FTC’s recent intervention into PBM economics.

Executive Context

In February 2026, the Federal Trade Commission issued a Decision and Order against Express Scripts, Evernorth Health, Medco, and Ascent Health Services. While the Order applies directly only to those entities, its implications extend far beyond a single PBM.

One provision in particular, the requirement that rebates be applied at the point of sale, has the potential to fundamentally alter how employers experience pharmacy costs, renewals, and negotiating leverage.

This paper focuses intentionally on that single provision. Not because it is the loudest reform in the Order, but because it is arguably the most destabilizing to the status quo.

Section I: How the Rebate System Actually Works Today

If rebates were as straightforward as the industry claims, they would not need to be explained so often.

The modern pharmacy rebate system is usually described as a savings mechanism. Manufacturers offer rebates. PBMs negotiate them. Carriers and plans use them to offset costs (if they are “passed through” to the plans). Premiums are lowered.

That description is tidy. It is also incomplete.

In practice, rebates function as delayed financial corrections layered on top of an intentionally inflated pricing system. They are retrospective, pooled, and invisible at the moment when costs are felt most acutely by members and evaluated most critically by employers.

Most prescription drug claims today are adjudicated using list prices that bear little resemblance to the drug’s true economic cost. Member cost sharing is calculated using those inflated prices. Deductibles, coinsurance, and copays anchor to numbers everyone in the system quietly acknowledges are fictional.

The rebate arrives later. Sometimes, much later.

By the time it does arrive, the member experience is already over. The pharmacy was paid. The patient paid. The claim is closed.

Whatever correction the rebate provides happens later, upstream, removed from the point of care and from employer decision-making.

This separation of cost and correction creates distorted incentives. Manufacturers are rewarded for raising list prices. PBMs are rewarded for maximizing rebate volume. Carriers are rewarded for using rebates to smooth pricing volatility. Members absorb higher out-of-pocket costs. Employers are left negotiating renewals using incomplete information.

None of this requires bad actors. It only requires time delays and complexity.  And there’s an abundance of both in the current system.

Section II: What the FTC’s Decision and Order Says About POS Rebates

The FTC’s Decision and Order against Express Scripts directly challenges the economic logic that has governed PBM operations for decades.

Among its most consequential provisions, the Order requires that members receive the benefit of manufacturer rebates at the point of sale. Member out-of-pocket costs may not be based on list price or any benchmark higher than the net unit cost of the drug.

This is not guidance. It is a binding behavioral requirement.

However, the Order does not require pharmacies to hand cash to patients. It does not require negative copays. It does not eliminate rebates.

It requires expected rebates to be accounted for upfront when claims are adjudicated. 

Here’s an example that will make sense to everyone.  If you are covered by a high-deductible health plan, and the price of the drug at the pharmacy counter is $500, you pay $500.  But if the NET price of the drug, after a $200 manufacturer REBATE is applied, the price drops to $300 at the point of sale, and you would pay $300 vs. $500.  This provision is also applicable to FULLY-INSURED plans that Cigna offers.

Section III: Why Point-of-Sale Rebates Change the Loss Ratio Story Employers Hear at Renewal

For most employers, the renewal conversation follows a familiar script.

You sit down with your broker and carrier. They walk through claims experience. They show you your loss ratio. The loss ratio becomes the justification for what comes next.

Your loss ratio was high. Your plan underperformed. Your rates need to go up.  Same story, different year, right?

What often goes unsaid is that the loss ratio employers see at renewal is not a clean measure of true cost. It is built on gross pharmacy claims that intentionally exclude rebates.

In fully insured plans, pharmacy claims are recorded near list price. That inflated claim value flows directly into the loss ratio used in renewal discussions. Rebates sit elsewhere. They are pooled. They are applied retrospectively. They influence enterprise pricing, not plan-level storytelling.

When an employer is told their loss ratio is 90%, that figure almost always reflects drug claims that will later be partially offset by rebates the employer never sees itemized or attributed back to their plan.

This is standard practice. It is also narrative control.

Point-of-sale rebates collapse that distortion. When rebates are applied upfront, pharmacy claims reflect net cost. Claims come in lower. Loss ratios improve.

Not because utilization changed. Not because members became healthier. But because inflated pricing has been removed from the math. 

More importantly, it removes a powerful renewal lever. Carriers can no longer inflate claims first and explain the correction later. The correction already happened and it’s reflected in the claims data and the loss ratio.  They lose, to a good degree, the biggest and most frequently used excuse to raise your premiums.

For employers, this changes the conversation. If the loss ratio looks reasonable, why is the increase still required? If pharmacy trend appears modest, why is drug spend framed as the primary driver?

Point-of-sale rebates do not weaken carriers financially. They weaken the story employers have been conditioned to accept, year after year – “claims are claims, and there’s nothing you can do about them.  And claims were bad so here’s your increase”.

Section IV: Premiums, Tradeoffs, and the Question Employers Actually Care About

Employers will inevitably ask whether point-of-sale rebates will cause premiums to rise.  If those rebates can no longer be used to subsidize premium, wont premiums go up?

In some fully insured plans, modest increases are possible, but not a guarantee. Rebates today are often used to suppress premiums. When rebates are applied earlier at the point of sale, they are no longer available to quietly offset premiums later, but I’ve already explained how up-front POS rebates could positively impact the loss ratio, and therefore the rates.

Regulators understand this tradeoff. They would rather see premiums reflect real expected costs than allow premiums to be cosmetically lowered by charging sick members more at the pharmacy counter (I’ll explain this in a moment).

What is often overstated is the permanence of that effect.

If net claims fall and loss ratios drop too far, medical loss ratio rules force correction. Carriers must either reprice premiums downward in future cycles or issue MLR rebates.

Point-of-sale rebates compress timing. They force pricing discipline sooner. They reduce the ability to delay reconciliation.

For employers, the real question is not whether premiums move, it is whether premiums are being explained honestly.

A premium increase driven by real net cost is fundamentally different from an increase justified by inflated claims that will be corrected later in ways the employer cannot see and does not benefit from.

Point-of-sale rebates do not eliminate cost. They eliminate illusion.

For CFOs, HR leaders, and public-sector buyers alike, that clarity matters a great deal.

And to address the issue of charging sick members more at the pharmacy counter, here’s the explanation.

Under the current system, people who take expensive medications are often paying based on a price that nobody actually expects to be the final cost.  Like in the HSA example I used before.  When a person pays $500 for a med that everyone knows will get a rebate LATER, that individual doesn’t see any direct affect, they pay full gross price at the pharmacy.  Then months later, the rebate is paid back to the plan/employer, or kept by the PBM or the carrier.  Maybe the employer/plan uses it to reduce premiums for everyone….maybe they don’t.

So, the reality is, the person taking the medication overpays at the pharmacy counter so the rest of the group can maybe pay slightly less in premiums.

That is the sick subsidizing the healthy.

Point-of-sale rebates don’t make drugs cheap. They simply stop charging sick people based on prices everyone knows will later be corrected via the rebate.

Instead of overpaying upfront and subsidizing the group quietly, the cost is spread where it belongs: across the entire risk pool, through premiums that reflect real net costs.

That is the shift regulators are pushing. Not generosity. Fairness.

Section V: Why This Single Provision Creates Employer Leverage

Point-of-sale rebates do not require employers to demand anything. They create leverage by changing what is visible.

When claims reflect net cost, loss ratios are cleaner. Trend assumptions are harder to inflate. Renewal explanations must be simpler or more defensible.

Employers gain the ability to ask better questions without escalating conflict.

Leverage does not come from ultimatums. It comes from clarity, and this is a lesson we are learning in spades.  With more transparency, comes more clarity.  With more clarity, comes more understanding and knowledge.  And with those….well, we are seeing different actions, different decisions by employers.  We are seeing progress.

Conclusion: Why Rebate Sorcery Is Ending

The FTC’s intervention into PBM economics is a signal that something fundamental is changing. Not because the system suddenly became broken, but because the way it has been working is no longer acceptable to explain, defend, or ignore.

For a long time, pharmacy pricing has relied on intentional delay. Prices are high upfront. Corrections come later. Employers are told everything nets out in the end. Members are asked to absorb the difference in the meantime, and mainly sick members. Technically, that may work. Practically, it has created a system where the people who use healthcare the most pay the highest price for everyone else’s stability.  Maybe you think that’s fair?

Point-of-sale rebates challenge that structure. Not by eliminating rebates, and not by making drugs inexpensive, but by forcing the correction to happen earlier. When cost-sharing reflects net cost instead of list price, the math becomes harder to manipulate and easier to understand.

That shift matters for employers.

It changes how loss ratios look at renewal. It changes how pharmacy trend is explained. And it changes where leverage actually sits in the conversation. When inflated numbers disappear, explanations have to get better. Assumptions have to get tighter. And renewal discussions become about actual performance instead of reconciliation.

This is about accountability. It is about aligning what members pay with what employers are shown, and what plans actually spend.

Rebate sorcery is ending because the gap it depends on is closing. Employers are asking better questions and regulators are setting clearer expectations.

For employers, clarity does not guarantee lower costs. But it does guarantee something just as important: the ability to see what is really happening, and to negotiate from a position grounded in reality.

And that, more than any single provision, is why this change matters.